Aldesleukin

• Use of low doses of interleukin-2 in autism spectrum disorders Pending
  2025-522841-23-00 Phase II 1 country Assistance Publique Hopitaux De Paris
• A Phase 1/2a Study of UCART20x22 in B-Cell Non-Hodgkin Lymphoma [NatHaLi-01] Recruiting
  2022-501607-27-00 Phase I (FiH) 3 countries Cellectis
• Study to investigate lifileucel regimen plus pembrolizumab compared with pembrolizumab alone in participants with untreated, advanced melano… Recruiting
  2022-503140-41-00 Phase III 12 countries Iovance Biotherapeutics Inc.
• A clinical study to investigate if the investigational product, called LN -145 (also known as Tumor Infiltrating Lymphocytes) is safe and be… Recruiting
  2024-510778-26-00 Phase II 6 countries Iovance Biotherapeutics Inc.
• A First-In-Human, phase I/IIa, open-label trial assessing safety, tolerability, and feasibility of repeated administrations of a novel autol… Recruiting
  2025-521227-70-00 Phase I (FiH) 1 country CuraCell Holding AB
• PANCEP-1 Recruiting
  2023-506979-10-00 Phase I/II 1 country Vaestra Goetalandsregionen
• A phase I/II study of CAR-expressing Allogenic iPSC derived NK cells for treatment of autoiMmune disease by B cELl depletion - CARAMEL Recruiting
  2024-519532-16-00 Phase I/II 1 country Universitaetsklinikum Erlangen AöR
• Phase II randomized study evaluating a Pragmatic approach to Adoptive Cell Therapy (ACT) using an IL2 analog (ANV419) vs High dose IL2 after… Recruiting
  2023-506400-99-00 Phase II 3 countries Vall D Hebron Institute Of Oncology
• Safety and efficacy of low-dose interleukin-2 therapy in chronic inflammatory barrier diseases (IL-2-ID) Recruiting
  2023-510297-14-00 Phase II 1 country Universitaetsklinikum Schleswig-Holstein AöR
• DFIL2-REP - Study of the clinical and biological response to repeated administration of low-dose interleukin-2 in patients with type 1 diabe… Recruiting
  2024-514043-29-00 Phase II 1 country Assistance Publique Hopitaux De Paris
• A phase II study on adjuvant vaccination with dendritic cells loaded with autologous tumor homogenate in resected stage IV rare cancers: neu… Recruiting
  2023-510251-31-00 Phase II 1 country Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.
• Vaccination with autologous dendritic cells loaded with autologous tumour homogenate after curative resection for stage IV colorectal cancer… Recruiting
  2024-516221-31-00 Phase II 1 country Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.
• Infusion of ex vivo-generated allogeneic natural killer cells in combination with subcutaneous IL-2 in patients with acute myeloid leukemia:… Ended
  2024-515357-16-00 Phase II 1 country Stichting Radboud universitair medisch centrum
• Therapeutic evaluation of low-dose IL-2-based immunomodulatory approach in patients with early Alzeihmer Disease Ended
  2024-516565-36-00 Phase II 1 country Groupe Hospitalier Universitaire Paris Psychiatrie Et Neuroscience
• A phase 2, Multicenter Study of TILs Treatment in Advanced Tumors with Alterations in the SWI/SNF Complex: the TILTS Study Ended
  2023-504632-17-00 Phase II 1 country Fundacio Institut D Investigacio Biomedica De Bellvitge IDIBELL
• A two-part, open-label, clinical study to assess the safety, tolerability and activity of intravenous doses of ICT01 in combination with low… Ended
  2024-514758-65-00 Phase I (FiH) 2 countries Imcheck Therapeutics
• A clinical study to investigate if the investigational products, called LN-144 and LN-145 (also known as Tumour Infiltrating Lymphocytes), a… Ended
  2024-510779-39-00 Phase II 3 countries Iovance Biotherapeutics Inc.
• A study to find out if an investigational product, called LN-145 (also called tumor infiltrating lymphocytes) is an effective and safe treat… Ended
  2024-510634-41-00 Phase II 5 countries Iovance Biotherapeutics Inc.
• A study of lifileucel (tumor-infiltrating lymphocytes) in adults with advanced melanoma Ended
  2025-522054-40-00 Phase II 4 countries Iovance Biotherapeutics Inc.

Showing 1–19 of 19 trials